QIAGEN Signs Definitive EQT Deal at €46.50/Share; Q3 Sales $548M, FY26 Outlook Suspended
QGEN sits 56% above its 52-week low of $32.53 on elevated volume (4.6× avg).
Summary
QIAGEN signed a definitive agreement to be acquired by EQT Private Equity at €46.50 per share in cash, valuing the company at about €10.8 billion enterprise value, with closing expected mid-2027. It also reported preliminary Q3 2026 net sales of $548 million and EPS of $0.65 and suspended its 2026 outlook.
Key Events · M&A and Partnerships · QGEN
-
EQT Takeover Agreement Signed
Crown NL Bidco B.V., backed by EQT XI with ADIA and CPP Investments co-investors, will offer €46.50 per share in cash for all QIAGEN shares under a Business Combination Agreement dated October 21, 2026.
-
40.3% Premium to Unaffected Price
The €46.50 offer is a 40.3% premium to the €33.15 XETRA close on July 8, 2026 and 46.9% above the three-month VWAP of €31.66; enterprise value is about €10.8 billion (~$12.1 billion) including roughly $1.1 billion of net debt.
-
50% Threshold, 80% EGM Hurdle
The offer needs 50% of outstanding share capital plus one share tendered; the Post-Closing Measures that would squeeze out remaining holders require 80% of votes cast at the EGM, otherwise the boards may proceed at their fiduciary discretion.
-
Q3 Sales $548M, Outlook Suspended
Preliminary Q3 2026 net sales were $548 million at both reported and constant exchange rates, with adjusted diluted EPS of $0.65; the full-year 2026 outlook is suspended while the transaction is pending.
Analysis · QGEN · Life Sciences
Hard terms are now on the table for the EQT takeover that until now had been only press-reported: a signed Business Combination Agreement dated October 21, 2026 at €46.50 per share in cash, a 40.3% premium to the €33.15 unaffected XETRA close on July 8, 2026, and roughly €10.8 billion (~$12.1 billion) enterprise value including about $1.1 billion of net debt. The deal needs only 50% plus one share tendered, but full ownership via the Post-Closing Measures hinges on 80% approval at an EGM, and non-tendering holders would then get a cash distribution net of withholding — potentially less than the offer. Closing is expected mid-2027 with no financing condition, and if regulatory approvals slip past 10 months QIAGEN may pay an interim dividend of up to $0.47 per share. Alongside the deal, QIAGEN disclosed preliminary Q3 2026 net sales of $548 million and adjusted diluted EPS of $0.65 and suspended its full-year 2026 outlook — so the standalone earnings story is now frozen until the transaction resolves.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 46.3% of the 283 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QGEN was trading at $50.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.3B. The 52-week trading range was $32.53 to $57.82. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.